Voriconazole use and pharmacokinetics in combination with interferon-γ for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir

Medical Mycology

Volumn 48, Issue 3, 2010, Pages 532-536

  Nierenberg, Natalie E ^a   Thompson III, George R ^b,e   Lewis II, James S ^b,c   Hogan, Brian K ^d   Patterson, Thomas F ^b,e  

^a Division of General Medicine   (United States)

^b Division of Infectious Diseases   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Cryptococcus; Salvage; Therapeutic drug monitoring; Voriconazole

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VORICONAZOLE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MONITORING; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; LUMBAR PUNCTURE; MALE; MINIMUM INHIBITORY CONCENTRATION; NIGHT SWEAT; PLEOCYTOSIS; RECURRENT DISEASE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; DIDEOXYNUCLEOSIDES; DRUG MONITORING; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; LAMIVUDINE; MALE; MENINGITIS, CRYPTOCOCCAL; PYRIMIDINES; RITONAVIR; SERUM; TRIAZOLES; YOUNG ADULT;

EID: 77950555366     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903325282     Document Type: Article

References (20)

1. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-718.
2. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and effi cacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396.
3. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745-755. (Pubitemid 41487778)
4. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for lesscommon, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
5. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferongamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189: 2185-2191. (Pubitemid 38757190)
6. Thompson GR, III, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53: 309-311.
7. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-1572.
8. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525-530.
9. Thompson GR, III, Rinaldi MG, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009; 53: 2223-2224.
10. Posaconazole FDA Briefi ng Document. Accessed 17 February 2009 from: http://www.fda.gov/cder/foi/nda/2006/022003s000-Noxafi l- TOC.htm
11. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167. (Pubitemid 40656221)
12. Trifi lio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-1535. (Pubitemid 46595688)
13. Liu P, Foster G, Gandelman K, et al. Steady-state pharmac okinetic and safety profi les of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51: 3617-3626. (Pubitemid 47519352)
14. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves effi cacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211. (Pubitemid 351269158)
15. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739-742. (Pubitemid 46032197)
16. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-243. (Pubitemid 43146453)
17. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fl uid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-732. (Pubitemid 37100817)
18. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645. (Pubitemid 41510735)
19. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26: 1266-1269.
20. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46: 437-442.